G06F 19/20(20130101), C12Q 1/6886(20130101), C12Q 2600/118(20130101), C12Q 2600/158(20130101)
The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient.
Chen, Dung-Tsa and Yeatman, Timothy J., "Malignancy-risk signature from histologically normal breast tissue" (2015). USF Patents. 72.
H. Lee Moffitt Cancer Center and Research Institute, Inc.